文献速递产科母胎医学

妊娠期轻度慢性高血压的治疗:成本-效果分析

Treating Mild Chronic Hypertension During Pregnancy: A Cost-Effectiveness Analysis.
PubMed 文献 · Obstet Gynecol · 2024-02-22

本研究构建决策分析模型,在18万例轻度慢性高血压孕妇中比较按轻度范围血压(140/90 mm Hg)治疗与按重度范围血压(160/105 mm Hg)治疗的成本效果。结果显示,较低阈值治疗可减少子痫前期、重度子痫前期、严重孕产妇病率、早产、孕产妇死亡、新生儿死亡及神经发育迟缓,并节省6亿美元、增加12,852个质量调整生命年,为优势策略。

要点

  • 按140/90 mm Hg阈值治疗较160/105 mm Hg阈值减少子痫前期14,177例。
  • 较低阈值治疗减少严重孕产妇病率817例、孕产妇死亡18例。
  • 较低阈值治疗减少早产8,078例、新生儿死亡26例、神经发育迟缓157例。

核心结论

  • 按轻度范围血压(140/90 mm Hg)阈值治疗妊娠期慢性高血压是优势策略,成本更低、结局更好,且较按重度范围血压(160/105 mm Hg)治疗的标准化方案减少新生儿和孕产妇死亡。

研究设计与样本

  • 构建决策分析模型,在18万例轻度慢性高血压孕妇的理论队列中,比较按轻度范围血压(140/90 mm Hg)治疗与按重度范围血压(160/105 mm Hg)治疗慢性高血压。
  • 概率、成本和效用值来源于文献,并在敏感性分析中变化。
  • 成本效果阈值为每质量调整生命年100,000美元。

主要发现

  • 按轻度范围血压治疗较按重度范围血压治疗减少子痫前期14,177例(43,953 vs 58,130),其中重度子痫前期减少11,835例(40,530 vs 52,365)。
  • 减少严重孕产妇病率817例(4,375 vs 5,192),减少孕产妇死亡18例(102 vs 120)。
  • 减少早产8,078例(22,000 vs 30,078),进而减少新生儿死亡26例(276 vs 302)和神经发育迟缓157例(661 vs 818)。
  • 较低阈值治疗为优势策略,成本降低6亿美元,效果增加12,852个质量调整生命年。

关键数值与推荐

  • 成本效果阈值为每质量调整生命年100,000美元。
  • 主要结局包括每质量调整生命年的增量成本、子痫前期、重度子痫前期、严重孕产妇病率、早产、孕产妇死亡、新生儿死亡和神经发育迟缓。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the cost effectiveness of targeting a blood pressure of less than 140/90 mm Hg compared with 160/105 mm Hg. METHODS: A decision-analytic model was constructed to compare the treatment of chronic hypertension in pregnancy at mild-range blood pressures (140/90 mm Hg) with the treatment of chronic hypertension before 20 weeks of gestation at severe-range blood pressures (160/105 mm Hg) in a theoretical cohort of 180,000 patients with mild chronic hypertension. Probabilities, costs, and utilities were derived from literature and varied in sensitivity analyses. Primary outcomes included incremental cost per quality-adjusted life-year (QALY), cases of preeclampsia, preeclampsia with severe features, severe maternal morbidity (SMM), preterm birth, maternal death, neonatal death, and neurodevelopmental delay. The cost-effectiveness threshold was $100,000 per QALY. RESULTS: Treating chronic hypertension in a population of 180,000 pregnant persons at mild-range blood pressures, compared with severe-range blood pressures, resulted in 14,177 fewer cases of preeclampsia (43,953 vs 58,130), 11,835 of which were cases of preeclampsia with severe features (40,530 vs 52,365). This led to 817 fewer cases of SMM (4,375 vs 5,192), and 18 fewer cases of maternal death (102 vs 120). Treating at a lower threshold also resulted in 8,078 fewer cases of preterm birth (22,000 vs 30,078), which led to 26 fewer neonatal deaths (276 vs 302) and 157 fewer cases of neurodevelopmental delay (661 vs 818). Overall, treating chronic hypertension at a lower threshold was a dominant strategy that resulted in decreased costs of $600 million and increased effectiveness of 12,852 QALYs. CONCLUSION: Treating chronic hypertension at a threshold of mild-range blood pressures is a dominant (lower costs, better outcomes) and cost-effective strategy that results in fewer neonatal and maternal deaths compared with the standard treatment of treating at severe range blood pressures.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Doshi U, Chaiken S, Hersh A, et al. Treating Mild Chronic Hypertension During Pregnancy: A Cost-Effectiveness Analysis. Obstet Gynecol. 2024. PMID: 38387029. doi:10.1097/AOG.0000000000005531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。